

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

#### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Given Name (First Name)  Dermot	2. Surname McGovern	e (Last Name) 1	3. Date 05-November-2018  Corresponding Author's Name NA					
4. Are you the corresponding author?	Yes	✓ No						
5. Manuscript Title 2018-2019 ECCO Annual Disclosure of	f Potential Cor	nflicts of Inter	rest					
6. Manuscript Identifying Number (if you 2018-2019 ECCO Annual Disclosure of		nflicts of Inter	<b>F</b>					
Section 2. The Work Under	Consideration	on for Publi	ication					
Did you or your institution <b>at any time</b> recany aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of interest and the submitted work in the submit work in the submitted work in the submitted work in the submitt	ng but not limit erest?	ed to grants, d	lata monitoring	board, st	udy design, manuscript preparation,			
If yes, please fill out the appropriate in	iioiiiiatioii be	iow. Ii you na	ive more than	i one enti	ty press the ADD button to add a rov			
Excess rows can be removed by pressi			ive more than	one enti	ty press the ADD Button to add a lov			
Excess rows can be removed by pressi	ing the "X" bu	tton. Personal No	on-Financial Support?	Other?	Comments			
Excess rows can be removed by pression Name of Institution/Company	ing the "X" bu	ersonal No	on-Financial					
Excess rows can be removed by pression Name of Institution/Company unbiologics	ing the "X" bu	Personal No	on-Financial		Comments			
Excess rows can be removed by pression of Institution/Company  u Biologics  ridge Therapeutics	ing the "X" bu	Personal No	on-Financial		<b>Comments</b> Consulting			
Excess rows can be removed by pression of Institution/Company  u Biologics  ridge Therapeutics	ing the "X" bu	Personal No Fees?	on-Financial		Consulting Consulting			
Excess rows can be removed by pression of Institution/Company  u Biologics  ridge Therapeutics  fizer  ilead	ing the "X" bu	Personal No Fees?	on-Financial		Comments  Consulting  Consulting  Consulting			
Excess rows can be removed by pression of Institution/Company  Biologics  Fidge Therapeutics  Fizer  Filead	ing the "X" bu	Personal No Fees?	on-Financial		Comments  Consulting  Consulting  Consulting  Consulting			
Excess rows can be removed by pression in the pression of the pression in the	ing the "X" bu	Personal No Fees?	on-Financial		Comments  Consulting  Consulting  Consulting  Consulting  Consulting			
Excess rows can be removed by pressi	Grant? F	Personal No Fees?	on-Financial		Consulting Consulting Consulting Consulting Consulting Consulting Consulting Consulting			
Excess rows can be removed by pression in the pression of the pression in the	Grant? F	Personal No Fees?	on-Financial		Consulting Consulting Consulting Consulting Consulting Consulting Consulting Consulting			
Excess rows can be removed by pression in the pression of the pression in the	Grant? F	Personal No Fees? S	on-Financial Support?	Other?	Consulting Consulting Consulting Consulting Consulting Consulting Consulting Consulting			



Continue A						
Section 4. Intellectua	l Property Paten	ts & Copyrights				
Do you have any patents, when If yes, please fill out the approp Excess rows can be removed b	oriate information bel	ow. If you have m	•		✓ Yes	d a row.
Patent?	Pending? Issued	Licensed? Roy	alties <mark>?</mark> Lic	ensee?	Comments	
Genetic Associations with stricturing Crohns disease	<b>✓</b>					
Genetic Associations with severe UC	<b>✓</b>					
Genetic Associations with non- response to anti-TNF therapy	<b>✓</b>					
Section 5. Polationsh						
Relationsh	nips not covered ab	ove				
Are there other relationships o potentially influencing, what y		•	o have influ	enced, or tha	t give the appearance of	:
Yes, the following relations	hips/conditions/circu	mstances are pres	ent (explain	below):		
✓ No other relationships/con	ditions/circumstances	s that present a po	otential conf	lict of interes	t	
At the time of manuscript acce On occasion, journals may ask						ements
Section 6. Disclosure	Statement					
Disclosure			1. 1			
Based on the above disclosure below.	s, this form will autom	natically generate	a disclosure	statement, w	hich will appear in the b	OX
Dr. McGovern reports personal personal fees from Gilead, per Janssen, during the conduct Crohns disease pending, a pat non-response to anti-TNF ther	sonal fees from Merck of the study; In addit ent Genetic Association	k, personal fees fro ion, Dr. McGovern	m Precision has a paten	IBD Inc, gran It Genetic Ass	ts and personal fees fror sociations with stricturin	n g



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.